Our President and Founder, Jan Heybroek, was invited by PM360 to comment on recent concerns about the quality of (oncology) market research. The need to quickly track new product performance in priority markets is a key driver for this anxiety. This is relevant since standard prescription data, multi-disciplinary patient management, and varied institutional settings provide a scattered picture of the oncology market.
The industry can take major steps to ensure receipt of impeccable oncology market intelligence on a consistent basis. Jan provides 6 key measures to consider. Read his full column in PM360.
For more information on how MDoutlook provides impeccable and actionable disease intelligence, navigate our site and contact us here.